Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2017

View Archived Issues

Finch Therapeutics enters collaboration with OpenBiome to develop FIN-403

S100B and CX3CR1-expressing monocytes found to be involved in brain atrophy in HIV

Funding supports DMD Therapeutics as it moves DMD-813 into drug development

GSK initiates phase I study of GSK-2292767 in healthy subjects who smoke cigarettes

Bayer initiates phase I trial of BAY-1834845

Novel murine models of NPC present main neurobehavioural and molecular features of the disease

Phase III results for utidelone plus capecitabine in heavily pretreated metastatic breast cancer

ATHOS-3 phase III study of LJPC-501 meets primary efficacy endpoint

U.S. orphan status given to eFT-508 for diffuse large B-cell lymphoma

First-in-class p300/CBP inhibitor shows potential for treating castration-resistant prostate cancer

FDA orphan drug status given to abatacept for giant cell arteritis, idiopathic inflammatory myopathy

BioCryst reports interim results from phase II Apex-1 trial of BCX-7353 in HAE

Advaxis and Sellas sign license agreement to develop cancer immunotherapy agent

FDA clears GtreeBNT to conduct phase III trial of RGN-137 in epidermolysis bullosa

Renal markers found to correlate with tenofovir-associated toxicity

Pieris grants Aska option to license PRS-080 in Japan

Cellectar updates progress of phase I trial of CLR-131 in multiple myeloma

FDA approves Qtern for type 2 diabetes

Clearside moves resources from axitinib wet AMD program to Zuprata DME development

Helix BioPharma licenses rights to anti-CEACAM6 antibody from NRC

Novo Nordisk seeks Japanese approval of once-weekly semaglutide for type 2 diabetes

Exelixis enters into clinical collaborations for cabozantinib

Arsanis signs license agreement with Adimab for rights to antibodies targeting RSV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...